GE Healthcare Launches New Software to Expand Biacore T200’s Capabilities for Highly Sensitive, Focused Screening

11 Jun 2013

Product news

Biacore™* T200 Software v.2.0 enhances the capabilities of Biacore T200, offering researchers a flexible and powerful tool for efficient processing of molecular interaction data. Together, they facilitate label-free screening of low molecular weight compounds and low abundance proteins, giving detailed binding profiles on molecule-drug candidate mechanisms of action that ultimately assist in earlier lead selection and optimization.

The new software simplifies and speeds up the generation and transformation of raw label-free interaction data into high-quality information, reducing the time needed for screening and hit validation. Versatile, easy-to-use wizards guide assay set up, and options are available for designing custom assays, making Biacore T200 ideal for a multi-user environment.

The new software encompasses algorithms for efficient ranking and qualification of binders versus non-binders, and enables comparison of datasets through normalization of sample responses by a number of means. By performing detailed evaluation of a single sample or co-evaluating up to 5000 single-concentration samples from multiple runs with the same ease, Biacore™ T200 Software v.2.0 significantly reduces the time required for evaluation of large lead series.

Links

Tags

High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Drug TestingIt is essential to test the efficacy and toxicity of drugs at every stage of their development to ensure that a pharmaceutical product is fit for purpose and safe for use before reaching the stage of mass production and distribution.Compound ScreeningCompound screening is a method used to discover specific compounds that could be promising candidates for pharmaceutical use. This potential is identified when compounds interact with the target protein during screening and could therefore be carried forward in the drug development process.
GE Healthcare Launches New Software to Expand Biacore T200’s Capabilities for Highly Sensitive, Focused Screening